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Background: Patients with prostate cancer face the difficult decision between a wide range of therapeutic options.
These men require elaborate information about their individual risk profile and the therapeutic strategies´ risks and
benefits to choose the best possible option. In order to detect time trends and quality improvements between an
early patient population (2003/2004) and a later reference group (2007/2008) data was analysed with regards to
epidemiologic parameters, differences in diagnostics and the type and ranking of the recommended therapies
taking into account changes to Gleason Grading System and implementation of new therapeutic strategies,
particularly Active surveillance, in 2005.
Methods: Data from all 496 consecutive patients who received consultation in 2003/2004 (n = 280) and 2007/2008
(n = 216) was retrospectively evaluated. Categorical variables were compared using the Chi-square test. Dependent
variables were analysed using the unpaired Students´ t-test and the Mann–Whitney U-test.
Results: The cohorts were comparable concerning clinical stage, initial PSA, prostate volume, comorbidities and
organ confined disease. Patients in Cohort I were younger (66.44 vs. 69.31y; p < .001) and had a longer life
expectancy (17.22 vs. 14.75y; p < .001). 50.9%, 28.2% and 20.9% in Cohort I and 37.2%, 39.6% and 23.2% in Cohort II
showed low-, intermediate- and high-risk disease (D´Amico) with a trend towards an increased risk profile in Cohort
II (p = .066). The risk-adapted therapy recommended as first option was radical prostatectomy for 91.5% in Cohort I
and 69.7% in Cohort II, radiation therapy for 83.7% in Cohort I and 50.7% in Cohort II, and other therapies
(brachytherapy, Active surveillance, Watchful waiting, high-intensity focused ultrasound) for 6.5% in Cohort I
and 6.9% in Cohort II (p < .001). Radiation therapy was predominant in both cohorts as second treatment option
(p < .001). Time trends showing quality improvement involved an increase in biopsy cores (9.95 ± 2.38 vs. 8.43 ±
2.29; p < .001) and an increased recommendation for bilateral nerve sparing (p < .001).
Conclusion: In the earlier years, younger patients with a more favourable risk profile presented for interdisciplinary
consultation. A unilateral recommendation for radical prostatectomy and radiation therapy was predominant. In the
later years, the patient population was considerably older. However, this group may have benefitted from
optimised diagnostic possibilities and a wider range of treatment options.
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At present, about 63.000 new cases of prostate cancer (PCa)
are diagnosed every year in Germany [1]. Increasing know-
ledge regarding the heterogeneity of PCa [2,3] and its vari-
able clinical course has sparked controversy over the best
treatment approach [4-6]. Between diagnostic and thera-
peutic uncertainty on the one hand, and overtreatment on
the other hand, physicians have an important obligation to
provide patients with complete information on treatment
options and their side effects [7]. The patient finds himself
confronted with various treatment options [8-11], and his
choice of treatment may also be substantially influenced
by other factors such as family considerations, social envir-
onment, social status, and the patient-consultant relation-
ship [12]. Many patients favour shared medical decision
making [13]. The usually long clinical course of PCa com-
plicates the choice of treatment. Comorbidity evaluation
also plays an important role in this context [14].
Since 2001, interdisciplinary consultation then sup-
ported by the German Cancer Aid (until 2006; project
number 70–2945) has been provided to approximately
2500 PCa patients by experienced urologists and radi-
ation therapists at the IPC [7]. The patients (and family
members) are informed face to face by the urologist and
radiation oncologist. Consultation contains a full over-
view of the possible therapeutic options with regard to
the information about the individual risk profile: pa-
tient’s age and comorbidities, medication, palpation find-
ings, PSA level, Gleason Score of biopsy, number of
positive biopsy cores, CT- or MRI scan, as far as known
at the time of consultation. The duration of the consult-
ation is variable and depends on the individual demands
of the patient or family members and varies averagely
between 15 to 60 minutes.
Important changes and new complements in prostate
cancer therapy around the year 2005 like the revision of
the Gleason Grading System [15], the implementation of
Active surveillance (AS) as a treatment option for low-risk
cancers and non-standardised therapeutic alternatives like
high-intensity focussed ultrasound (HIFU), cryotherapy or
laser-based ablation techniques, have led to a greater var-
iety of treatment options. In order to prove an impact of
these changes and complementary therapeutic options as
well as to evaluate the quality of our interdisciplinary con-
sultation, time trends between an early patient population
(2003/2004) and a later reference group (2007/2008) were
analysed with regard to epidemiologic factors and pre-
clinical diagnostics as well as changes in the type and
ranking of treatment recommendations.
Methods
Data from all 496 consecutive patients who received
interdisciplinary consultation in 2003/2004 (Cohort I;
n = 280) and 2007/2008 (Cohort II; n = 216) could beanalysed. The patients presenting for consultation had to
a great extent newly diagnosed, localised prostate cancer.
The majority of patients was diagnosed pre-clinically by
registered urologists and was then presented to the IPC
for interdisciplinary consultation. Also patients with ad-
vanced prostate cancers presented for consultation in
terms of a second opinion. As the patients presented for
a medical consultation with no additional invasive me-
dical procedures (e. g. additional blood samples etc.) and
not within the context of a clinical or experimental
study, no special ethical approvement was required (Eth-
ics Review Committee of the Charité-Berlin University
Medical Center; EA4/082/13). All patients gave their
written informed consent for the evaluation and pub-
lication of the anonymised data generated within the
context of the consultation. Analysis of the data en-
compassed important epidemiological parameters as far
as known at the time of consultation (clinical stage, PSA
at the time of diagnosis, biopsy Gleason score, D’Amico
risk group stratification, prediction of prognosis ac-
cording to Partin and Kattan, and Charlson comorbidity
score) as well as the type and ranking of the re-
commended therapies. The recommended therapies
were: radical prostatectomy (RP; open surgery, conven-
tional laparoscopic surgery, and robot-assisted laparo-
scopic surgery), external 3D-CT-planned external beam
radiation therapy (EBRT) with at least 73.8 Gy or IMRT,
brachytherapy (BT; Seeds or HDR brachytherapy), Ac-
tive surveillance (AS; since 2005), Watchful waiting
(WW), high-intensity focused ultrasound (HIFU; since
2005), and androgen deprivation (AD). For better pres-
entation and greater clarity, the focus lies on the first
two ranks of recommendation. Equally valid recommen-
dations were given the same ranking.
Over the years, patients received consultation from a
total of 17 urology specialists and 10 radiation oncology
specialists. Data was assessed on the basis of medical re-
cords and by questionnaires when necessary. Normal
distribution was verified by the Kolmogorov-Smirnov
test. Data analysis was done using SPSS software version
19.0 (SPSS Inc., Chicago Il, USA). Categorical variables
were compared using the Chi-square test. The unpaired
Students´ t-test and the Mann–Whitney U-test were
used for dependent variables as appropriate. The signifi-
cance level was set at .05.
Results
Epidemiology
PCa diagnosis was based on an elevated serum PSA level
for 86.8% of the patients in Cohort I and 88.9% of the
patients in Cohort II, suspicious palpation findings for
25% of the patients in Cohort I and 13.4% of the patients
in Cohort II, histology after transurethral resection of
the prostate (TURP) for 2.5% in Cohort I and 4.6% in
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Cohort I and 10.6% in Cohort II with no measurable
group differences (p > .05). Table 1 summarises the
symptoms or diagnostic findings which led to PCa
diagnosis.
At the time of interdisciplinary consultation, analysis
of the mean age of patients disclosed marked group
differences: 66.44 years in Cohort I vs. 69.31 years in
Cohort II (p < .001). The mean life expectancy was
17.22 years in Cohort I and 14.75 years in Cohort II
(p < .001). 70.9% of the patients in Cohort I and only
40.8% of the patients in Cohort II had a life expectancy
of more than 15 years (p < .001).
The median PSA value at the time of diagnosis was
7.98 ± 22.59 μg/l (0.4-311) in Cohort I and 7.6 ±
15.66 μg/l (0.88-120) in Cohort II with no group differ-
ences (p = .392).
Analysis of the number of cores in the diagnostic pros-
tate biopsy showed a significant group difference in
favour of Cohort II: 9.95 ± 2.38 (2–20) vs. 8.43 ± 2.29 (2–
14) in Cohort I; p < .001. The two cohorts did not differ
with regard to the prostate biopsy sites or the mean
prostate volume (40.16 ml ± 15.64 in Cohort I and
41.75 ml ± 19.56 (n = 66) in Cohort II; p = .689). The bi-
opsy Gleason score was 6 ± 1.43 in Cohort I and 6.59 ±
0.99 (p < .001) in Cohort II.
The clinical stages were distributed as follows: T1a-c
66.1% in Cohort I and 74.4% in Cohort II, T2a-c 28.8%
in Cohort I and 22.3% in Cohort II, T3 1.1% in Cohort I
0.5% in Cohort II and T4 0.7% in Cohort I and 0.5% in
Cohort II (missing: 3.3% in Cohort I and 2.3% in Cohort
II; p = .602).
There were no group differences concerning accom-
panying diseases measured by the Charlson comorbidity
score (CCS): 0.41 (0–6) in Cohort I and 0.39 (0–6) in
Cohort II (p = .787).
The groups were also comparable in terms of organ-
confined disease (T2) according to Partin Tables (2007)
(Cohort I: 61.12%; Cohort II: 58.98%; p = .324). The
Kattan nomogram predicted a 5-year biochemical failure
free survival of 79.79% in Cohort I and 79.16% in CohortTable 1 Symptoms or diagnostic findings leading to
prostate cancer diagnosis
Cohort I Cohort II p-value*
(%) (%)
Elevated PSA levels 86.8 88.9
>.05
Suspicious palpation 25 13.4
Histology after TURP 2.5 4.6
PCa associated symptoms 7.1 10.6
*Student´s T-test; Symptoms or diagnostic findings leading to PCa diagnosis:
elevated PSA levels, suspicious palpation of the prostate, incidental histology
after transurethral resection of the prostate (TURP) and PCa associated
symptoms.II (p = .735) after RP and a rate of 79.27% (Cohort I) and
79.77% (Cohort II; p = .657) after EBRT with no group
differences.
Patients were stratified by D’Amico classification into
low-, intermediate- and high-risk groups as follows:
50.9%, 28.2% and 20.9% in Cohort I; 37.2%, 39.6% and
23.2% in Cohort II, showing a trend towards an in-
creased risk profile in Cohort II (p = .066).
In Cohort I, 129/280 patients (46%) underwent pre-
operative bone scan, which was positive in 17 cases
(13.2%). If the current national or international guide-
lines [8,10,11] had been applied at that time, 120 of the
129 (93%) bone scans would have been indicated. In Co-
hort II, bone scan was performed in 75/216 patients
(34.7%) and was positive in 3 cases (4%). Based on the
current national- and international guidelines [8,10,11],
bone scan would have been indicated for 91 patients in
Cohort II.
At the time of consultation, 143/261 (54.7%) patients
in Cohort I and 86/191 (45%) in Cohort II were potent
in terms of erections adequate for sexual intercourse
(IIEF-5-Score ≥20). In this group of potent patients, the
preservation of potency was important to 85.3% in Co-
hort I and to 87.2% in Cohort II.
Table 2 summarises the epidemiological and clinical
parameters.
Treatment recommendations and ranking
In Cohort I, the D’Amico risk-adapted therapy recom-
mended as the first treatment option was RP for 91.5%,
EBRT for 83.7%, BT for 2.4%, and AD for 3.3% (p < .001).
The overlap in patients who received the equally valid rec-
ommendation for RP and EBRT was 33.9%. Predominant
in the second rating of recommendations in Cohort I was
EBRT (16%), followed by RP (8.5%; p < .001).
In Cohort II, the D’Amico risk-adapted therapy re-
commended as the first treatment option was RP for
69.7%, EBRT for 50.7%, AD for 2.4%, AS for 2.4%, BT for
1.9%, HIFU for 1.4%, and WW for 0.5% (p < .001). The
overlap in patients who received the equally valid recom-
mendation for RP and EBRT was 5.7%. Predominant in
the second rating of recommendations in Cohort II was
again EBRT (49%), followed by RP (30.3%), BT (3.7%), AD
(2.4%), AS (1.8%), and HIFU (1.4%; p < .001). The rankings
of recommendations are shown in Figure 1.
Cohort I patients with a recommendation for RP had a
mean age of 65.8 (50–78) years, Cohort II patients of
67.46 (48–78) years. No nerve sparing was recom-
mended in 34%, unilateral nerve sparing in 16.5% and
bilateral nerve sparing in 46.5%. In this context, there
was a group difference in favour of Cohort II patients
where no nerve sparing was recommended in 26%, uni-
lateral nerve sparing in 7.4% and bilateral nerve sparing
in 65.8% (p < .001; Figure 2).
Table 2 Epidemiologic parameters at the time of consultation
Cohort I Cohort II p-value*
(SD and/or range) (SD and/or range)
Age (mean) 66.44 69.31 .001
Life expectancy (mean) 17.22 14.75
.001







PSA value (μg/l) 7.98 ± 22.59 (0.4-311) 7.6 ± 15.66 (0.88-120) .392
Organ confined (Partin; mean; %) 61.1 58.9 .324
Risk groups (D´Amico; %)
low-risk 50.9 37.2
.066intermediate risk 28.2 39.6
high risk 20.9 23.2
Charlson comorbidity score 0.41 (0–6) 0.39 (0–6) .787
Biochemical failure free survival (Kattan; %)
RP 79.8 79.2 .735
EBRT 79.3 79.8 .657
Gleason score of biopsy (median) 6 ± 1.43 6.59 ± 0.99 <.001
Number of biopsy cores 8.43 ± 2.29 (2–14) 9.95 ± 2.38 (2–20) <.001
Prostate volume (ml) 40.16 ± 15.64 41.75 ml ± 19.56 .689
*Student´s T-test and Chi-Square-test as appropriate; Epidemiologic parameters at the time of consultation; mean age in years; mean life expectancy and
percentage of patients with life expectancy >15 years; clinical stage (in %; missing clinical stage: 3.3% in Cohort I and 2.3% in Cohort II); PSA value in μg/l;
percentage of organ confined disease according to Partin 2007; risk group stratification according to D´Amico (in %); Charlson comorbidity score; 5-years
biochemical failure free survival according to Kattan nomogram (in %); median Gleason score of biopsy; number of biopsy cores; prostate volume in ml.
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Cohort I (18%) and 23 in Cohort II (21.7%) were receiv-
ing long-term anticoagulant therapy with acetylsalicylic
acid, while 4 in Cohort I (10.4%) and 11 in Cohort II
(2.1%) were on long-term oral anticoagulation therapy
(e. g. phenprocoumon) with a slight trend towards an in-
creased number of recommendations for surgery in pa-
tients with anticoagulation therapy in favour of patients
in Cohort II (p = .083; not shown).
Patients with a recommendation for EBRT had a mean
age of 66.43 (50–81) years in Cohort I and 69.43 years
(48–85 years) in Cohort II. Of the patients with a rec-
ommendation for EBRT, 44 (21%) in Cohort I and 56
(27.8%) in Cohort II were advised to undergo pelvic
lymphadenectomy previous to radiation. Neoadjuvant
and/or adjuvant AD was recommended for 71 patients
(33.9%) in Cohort I and 66 (32.8%) in Cohort II. BT was
recommended for 34 (12.1%) patients in Cohort I and
30 (13.9%) in Cohort II without group differences. There
was a slight trend towards favouring EBRT for patients
over 70 years of age and RP for patients under the age of
70 (p = .069; not shown).
AS was not considered an option until 2005 and was
therefore only recommended for Cohort II patients. Atotal of 45 patients (20.8%) received the recommenda-
tion for AS as a treatment option in the first and second
rank of recommendations. Based on the definition of pa-
tients eligible for AS given by Klotz et al. [6], AS could
have been offered to 55 patients in Cohort II. Given the
risk profile of Cohort I, AS could have been recom-
mended for 78 patients (27.8%) in accordance with the
national and international guidelines [8,10,11].
AD alone was recommended for 14 patients (5%) in Co-
hort I and 13 (6%) in Cohort II. WW was recommended
as a treatment option for 2 patients in Cohort I (0.7%) and
for 3 patients in Cohort II (1.3%). HIFU was recom-
mended for 27 patients (12.5%) since 2005. A recommen-
dation of combined HIFU with pre-HIFU TURP was
given to 11 of these 27 patients (40.7%).
Discussion
This analysis disclosed differences in the age structure of
the two cohorts with a corresponding impact on the
recommended treatment options. It has confirmed an
age shift towards older patients with more widely vary-
ing forms of the disease. No significant group differences




Figure 1 Therapy recommendations in the first and second rank green = Prostatectomy/ RPx; blue = EBRT/ RTx/Radiation therapy; violet =
Brachytherapy; red = Androgen deprivation; light orange = Active surveillance; light blue = HIFU, petrol blue = Watchful waiting. a) Therapy
recommendations in Cohort I in the first rank (in percent (%)); *p-value calculated as Chi-Square-test; Intersections of equally valid
recommendations for Prostatectomy and EBRT are specified within the figure. b) Therapy recommendations in Cohort II in the first rank (in
percent (%)); *p-value calculated as Chi-Square-test; Intersections of equally valid recommendations for Prostatectomy and EBRT are specified
within the figure. c) Therapy recommendations in Cohort I in the second rank (in percent (%)); *p-value calculated as Chi-Square-test. d) Therapy
recommendations in Cohort II in the second rank (in percent (%)); *p-value calculated as Chi-Square-test.
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particularly difficult to analyse, since the revision of the
Gleason grading system in 2005 [15] caused a shift in
the risk profile from the majority of low-risk cases in
Cohort I to a majority of intermediate-risk cases in Co-
hort II. This shift was detectable across all risk groups
and was mainly due to the upgrading of Gleason score 6
to Gleason score 7a in up to 30%.
Time trends in the present patient population
Concerning prostate biopsy, there was a difference in
the number of biopsy cores taken in favour of the pa-
tients in Cohort II. In this context, the increased numberFigure 2 Recommendation for nerve sparing in patients with ´radical
*Chi-Square-test; Nerve sparing recommendation in patients with ´radical p
sparing´; yellow = ´unilateral nerve sparing´; green = ´bilateral nerve sparingof biopsy cores in the later cohort may be associated
with the release of recommendations given by the na-
tional ´S3-guidelines on PCa´- working group in 2007
[8] in accordance with international guidelines [10]
recommending 10 or more biopsy cores. The patients in
Cohort II seemed to have received the recommended
number of cores which may be interpreted as a sign of
quality improvement. On the other hand, taking more
cores does not necessarily mean an improvement of
quality taking into account, that the patients in Cohort
II were considerably older.
Another sign of quality improvement in terms of
guideline recommendations was the fact, that bilateralprostatectomy´ as first rank therapy recommendation.
rostatectomy´ as first rank therapy recommendation: red = ´no nerve
´.
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tients in Cohort II.
Our patient population also showed a distinct trend
with regard to the increased recommendation for sur-
gery in patients under anticoagulant therapy in favour of
Cohort II patients. Treatment with platelet aggregation
inhibitors is particularly common in the age group of pa-
tients with PCa. Especially in patients with newly-
implanted coronary stents, there seems to be consensus
that platelet aggregation inhibition should be continued
during RP.
As aforementioned there was a measureable difference
in the age structure and life expectancy between the two
cohorts. Obviously the increased therapeutic options
after 2005 may have led to a higher number of patients
presenting with more varying forms of the disease or at
later stages of the disease. Possibly these patients might
have been older than those newly diagnosed with local-
ised stages of the disease. On the other hand, since
guidelines have made it easier for registered urologists
to advise patients, those patients with clear preferences
for one of the treatment options were simply not
presented any more for consultation at the IPC. How-
ever, as these explanations are speculative, we do not
have a sufficient explanation to our observation.
In terms of age and therapy recommendations, we
found a trend towards favouring RP for patients under
70 years and EBRT for those over 70 years. This trend
could have been a result of the hypothesis at that time,
that older patients may have a poorer recovery of con-
tinence after surgery. However, in their recently pub-
lished analysis of 1636 patients, Kunz et al. showed that
patients over the age of 70 do not face higher surgical
risks and that they are not even at higher risk for post-
operative incontinence. Instead, surgery-associated mor-
bidity was mainly dependent on the patients’ preexisting
comorbidities [16].
Marked group differences were found especially in the
first rank of therapy recommendations. In the earlier
Cohort I, the standard therapies were predominant. Co-
hort II showed a marked percentage decrease in recom-
mendations for RP and EBRT as first treatment option.
One simple explanation of this observation might be
again that fewer patients with a low-risk profile and an
obvious preferation for one of the standard therapies
presented for consultation. Presumably, the decrease in
recommendation for RP or EBRT in the later cohort was
due to the above-mentioned shifts in the patients’ age
structure and risk profile and because of the introduc-
tion of AS and HIFU as new treatment options in 2005.
Therefore, the patients in the later cohort II may have
benefitted from the greater variety of treatment options.
In both cohorts, EBRT was recommended most often
in the second rank of recommendations.AS according to the commonly applied specifications
of Klotz et al. [6] was recommended for 20.8% of the pa-
tients in the later Cohort II in any rank. An even higher
proportion of the Cohort I patients (27.8%) would have
qualified for AS, if it had been available as a treatment
option at that time. It is interesting to note that AS as a
´no treatment´- or probably ´delayed treatment´ strategy
was the recommendation for as many as one-fifth of pa-
tients with PCa. In this respect, PCa probably has a top
position among tumor entities, but still there are diag-
nostic difficulties and uncertainties in the risk stratifica-
tion of these patients [17].
AD and WW were a first-rating recommendation in
basically only a few cases.
An interdisciplinary shared decision making-process as
presented here is time-consuming. However, providing a
detailed description of all treatment options leads to
high levels of patient satisfaction [7,18]. Apart from that,
comprehensive specialist consultation is of great import-
ance against the background of the current discussions
regarding overtreatment-induced side effects and high
costs on the one hand and the potential consequences
and uncertainty as well as additional expenses of delayed
treatment on the other hand.
A face to face setting with the patient is ideal to work
out the patient´s preferences. Meghani et al. recently
showed that men with prostate cancer may be divided
into subgroups with some men being likely to trade sur-
vival time to prevent potential treatment risks while
others may accept treatment risks and are unlikely to
trade survival time [19]. The vast majority of cancer pa-
tients of either gender desire maximal information. It
was demonstrated, however, that a significantly higher
proportion of those who did not want maximal informa-
tion were over the age of 70 [20]. There is considerable
individual variation in the amount of information re-
quired during consultation. However, patients attach im-
portance to receiving individual consultation and sha
ring treatment decisions [21,22]. Men with PCa expect
the physician to explain the diagnosis and describe the
treatment options. Discussing these expectations at the
beginning of a consultation session can lead to a satis-
factory consensus decision [23]. Decision making on the
basis of the best possible understanding enables patients
to realistically appraise their personal risk profile and the
potential side effects of therapy [24]. In an analysis of
3056 PCa patients, Resnick et al. showed that the satis-
faction of patients with their PCa treatment was not
negatively influenced to any great extent by the side ef-
fects of the therapy recommended [25].
A communication mistake can entail overloading pa-
tients with too much information [26]. Providing too lit-
tle information is a far more common error, however.
This is the main cause of a decisional conflict in those
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ment decision satisfaction particularly among patients
who perceived themselves as being well-informed and
therefore felt they had control over their disease and
symptoms [28]. The most important factor affecting the
treatment decision of PCa patients is the physician
[29-31]. Apart from family considerations, negative ex-
periences of other cancer patients also exert an import-
ant influence on the treatment decision [30]. Denberg
et al. showed that the treatment decision of many pa-
tients was determined by misconceptions and bad expe-
riences of other patients. Most patients did not change
their beliefs and judged the success of therapy in terms of
the same misconceptions [32]. In this context patients´
anxiety about the disease is widely underestimated. Efforts
are made to measure the influence of patients´ anxiety on
decision making in prostate cancer [33].
Despite the high number of cases and data density,
there is a lack of relevant information at the time of con-
sultation, particularly from the earlier years (Cohort I).
Missing information includes standardised quality-of-life
assessment (e. g. EORTC QLQ-C30, QLQ-PR25) and
evaluation of micturition (IPSS), erectile function (IIEF)
and continence (ICIQ-SF), which are considered stand-
ard in the pre- and post-therapeutic situation [34,35].
These data have been regularly collected since 2005.
However, no time trends can be investigated in this ana-
lysis due to the inadequate data collection in Cohort I.
Different limitations to the data provided lie in the
unicenter data collection and the lack of long-term clin-
ical courses. Since consultation was basically offered to
all patients, data on the treatment actually implemented
are not available in a relevant proportion of those who
presented for consultation but were not treated at the
IPC. Thus no statement can be made at present regard-
ing congruence between the recommended and the
implemented treatment. Strong efforts are currently be-
ing directed towards generating these data. Another fac-
tor limiting the quality of consultation is the large
number of physicians involved over the years. Even
though guideline specifications were continuously inte-
grated into the working procedures in regular quality
circles of the IPC, consultation quality still remains
dependent on the knowledge and conversation tech-
niques of the consultant.
Individualisation of PCa treatment is a reality. Never-
theless, the value of the various treatment options has
not yet been prospectively assessed in a multicenter
study. A study aimed at clarifying this question for pa-
tients in a low-risk situation of the disease is the on-
coming ´PREFERE´ trial [36]. Prospective comparative
evaluation of the effectiveness of the various treatment
options is necessary in order to prevent harm being
done to patients. Apart from enhanced transmission ofinformation, improvements in imaging [37] and ad-
vanced diagnostic procedures like the analysis of cir-
culating tumor cells [38] will lead to further indi
vidualisation of the treatment options. Learning pro-
grams like PIES (Prostate Interactive Educational Sys-
tem) and other similar decision aids may provide
standardised information and objective decision support
for patients, family members and physicians [39,40].
However these print- or web-based decision tools may
not be useful for every patient and need further im-
provements [41]. Decision aids may increase patients´
perception of the desease but it is not guaranteed that
they lead to an increase of shared decision making [42].
Last but not least, the possibility of free online access to
information about studies such as the ´Australian Can-
cer Trials´ [43] helps to optimise the information basis
for patients, family members and physicians.
Conclusion
Our analysis disclosed time trends between the two co-
horts. In the early years of interdisciplinary prostate cancer
consultation, younger patients with a considerably longer
life expectancy presented for consultation and a unilateral
recommendation for the standard therapies was therefore
predominant. In the later years, there was a greater variety
of treatment recommendations due to new therapeutic
options like AS and HIFU. Patients in the later cohort
may have benefitted from these additional treatment op-
tions, which, among other influences, may have reduced
the number of recommendations for the standard therap-
ies. Quality improvements over the years were seen in the
greater number of biopsy cores in accordance with the
recommendations of the national and international guide-
lines and the increased number of recommendations for
bilateral nerve sparing prostatectomy in Cohort II. An
interdisciplinary consultation for patients with newly diag-
nosed PCa is the gold standard with regard to comprehen-
sive patient information.
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